The FDA approved Intrabio’s Aqneursa (levacetylleucine) as the first treatment for ataxia-telangiectasia (AT), according to reports. The approval extends the company’s rare-disease platform beyond its prior authorization two years earlier for Niemann-Pick disease type C. Intrabio positioned Aqneursa as a treatment for the neurodegenerative, rare genetic condition characterized by progressive neurologic decline and immune dysfunction. The approval also consolidates Intrabio’s commercial momentum by demonstrating the drug’s ability to secure additional regulatory traction in related neurologic rare diseases. For the broader biotech market, the decision is a reminder of how small, mechanism-focused programs can progress rapidly when clinical benefit aligns with orphan-disease endpoints.